J&J image loses ground with consumers; Teva, BioSante win FDA nod for testosterone med;

@FiercePharma: Senator wants to attach drug-shortage measure to highway bill: 'Can't wait a year to get this done'--Reuters. Article | Follow @FiercePharma

> Johnson & Johnson ($JNJ) fell in a consumer ranking of corporate image to No. 7, after ranking in the top two for the last dozen years-- since Harris Interactive launched the poll. Report

> Teva Pharmaceutical Industries ($TEVA) and BioSante Pharmaceuticals ($BPAX) won FDA approval for a transdermal testosterone gel for treatment of hypogonadism. Article

> Sanofi ($SNY) inked a deal with Emcure Pharmaceuticals to sell Verorab, a rabies vaccine, in India. News

> Takeda Pharmaceutical said it plans to issue up to $3.2 billion in bonds over two years, to help finance its $12.6 billion acquisition of Nycomed. Story

> Texas is running out of execution drugs and may have to halt lethal injections this summer after drugmakers put restrictions on the necessary anesthetics. News

> Pediatricians are increasingly banning families that choose not to vaccinate their children; some cite worries of contagion in their waiting rooms. Report

Biotech News

@FierceBiotech: BioSante soars on FDA nod for testosterone gel, regains some ground after failure of female libido gel. News | Follow @FierceBiotech

@JohnCFierce: Touting preclin results for a hep C treatment? A desperate cry for attention. BioCryst. Release | Follow @JohnCFierce

@RyanMFierce: UnitedHealth is planning a cloud-based platform, initially for healthcare users, but maybe pharma down the line: Article | Follow @RyanMFierce

@FierceMedDev: Post-Grateful Dead player scores medical hit. Story | Follow @FierceMedDev

> Hep C drug deal frenzy can't be slowed by growing doubts. Article

> Corporate VCs crowd into $43M round for Celladon. News

Medical Device News

> Does Riata recall indicate subpar device surveillance? Story

> Cayenne closes $10M to advance sports med portfolio. Item

> Stryker's Hartman sees salary boosted to $750K, MacMillan negotiates separation agreement. News

> Atossa files for IPO in effort to raise $6M. Report

Drug Delivery News

> Ensysce says carbon nanotubes delivered cancer drug. More

> Titan plans Q3 NDA submission for controlled-release implantable addiction treatment. Article

> Microscopic booms: China, U.S. efforts mull explosive use of nanotech drug delivery. News

> Can Medasys' new drug pump challenge Medtronic? Piece

> FDA biosimilar draft guidance creates drug delivery leeway. Story

Biomarkers News

> Positive results for biomarker based diagnostic CardioSCORE. News

> Collaborators work to create urine test for active TB. Item

> Gates Foundation funds TB biomarker research. Piece

> Progranulin biomarker predicts 5-year outcomes. Article

And Finally... Antibiotics are no help for most sinus infections, despite their common use, a study found. Report

Suggested Articles

After a major label expansion in December, Amarin's Vascepa is preparing a major boom in sales with its marketing team nearly scaled up.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

Data on Roche's Polivy aren't yet enough to win support from England's cost watchdogs, who rejected the medicine based on long-term…